ERK inhibitors (Kalyra)

N/A

Report date: 2025/03/20 15:44:23
NME

Base Information

Drug NameERK inhibitors (Kalyra)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKalyra Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesKalyra Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A